European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period

Vestergaard, C.; Wollenberg, A.; Barbarot, S.; Christen-Zaech, S.; Deleuran, M.; Spuls, P.; Flohr, C.; Trzeciak, M.; Kobyletzki, L. von; Seneschal, J.; Paul, C.; Bieber, T.; Werfel, T.; Fölster-Holst, R.; Darsow, U.; Gieler, U.; Svensson, A.; Cork, M.; Stalder, J. -F.; De Raeve, L.; Kunz, B.; Simon, D.; Chernyshov, P.; Hijnen, D.; Gelmetti, C.; Ring, J.; Taieb, A.; de Bruin-Weller, M. und Thyssen, J. P. (2019): European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. In: Journal of the European Academy of Dermatology and Venereology, Bd. 33, Nr. 9: S. 1644-1659

Abstract

Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the treatment of pregnant or lactating women and for adults planning to have a child are often lacking. This position paper from the European Task force on Atopic Dermatitis (ETFAD) is based on up-to-date scientific literature on treating pregnant and lactating women as wells as adults with AD planning to have a child. It is based on the expert opinions of members of the ETFAD and on existing safety data on the proposed treatments, many of which are derived from patients with other inflammatory diseases or from transplantation medicine. For treating future parents, as well as pregnant and lactating women with AD, the use of topical treatments including moisturizers, topical corticosteroids, tacrolimus, antiseptics such as chlorhexidine, octenidine, potassium permanganate and sodium hypochlorite (bleach) is deemed to be safe. Ultraviolet (UV) therapy may also be used. Systemic treatment should be prescribed only after careful consideration. According to the opinion of the ETFAD, treatment should be restricted to systemic corticosteroids and cyclosporine A, and, in selected cases, azathioprine.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0926-9959
• Sprache: Englisch